{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-090172","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.015779+00:00","generated_at":"2026-05-18T18:17:05.231300+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Invivyd reports positive Phase 1/2 data for VYD2311 COVID-19 mAb; half-life up to 76 days","bullets":["All adverse events mild to moderate; no serious or severe AEs observed across IV, SC, and IM routes.","VYD2311 half-life by cohort: IM 76 days, high-dose IV 61 days, vs pemivibart's 49 days.","Dose modeling indicates IM dosing every 3 months may provide robust efficacy for immunocompromised and non-IC.","Type C meeting with FDA scheduled for early Q3 2025 to discuss registration path for VYD2311.","VYD2311 is 99%+ structurally identical to adintrevimab and pemivibart, with improved potency."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-090172","json":"https://secwatch.observer/filing/0000950170-25-090172.json","markdown":"https://secwatch.observer/filing/0000950170-25-090172.md","text":"https://secwatch.observer/filing/0000950170-25-090172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025090172/0000950170-25-090172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025090172/ivvd-20250626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:17:05.231300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}